BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35046060)

  • 1. Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity.
    Tully KM; Tendler S; Carter LM; Sharma SK; Samuels ZV; Mandleywala K; Korsen JA; Delos Reyes AM; Piersigilli A; Travis WD; Sen T; Pillarsetty N; Poirier JT; Rudin CM; Lewis JS
    Clin Cancer Res; 2022 Apr; 28(7):1391-1401. PubMed ID: 35046060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Korsen JA; Gutierrez JA; Tully KM; Carter LM; Samuels ZV; Khitrov S; Poirier JT; Rudin CM; Chen Y; Morris MJ; Bodei L; Pillarsetty N; Lewis JS
    Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2203820119. PubMed ID: 35759660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
    Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting angiogenesis for radioimmunotherapy with a
    Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of
    Pandey U; Kameswaran M; Gamre N; Dash A
    J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of [
    Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human imaging with [
    Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
    medRxiv; 2024 Jan; ():. PubMed ID: 38260492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.
    Korsen JA; Kalidindi TM; Khitrov S; Samuels ZV; Chakraborty G; Gutierrez JA; Poirier JT; Rudin CM; Chen Y; Morris MJ; Pillarsetty N; Lewis JS
    J Nucl Med; 2022 Sep; 63(9):1401-1407. PubMed ID: 35058323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Hens M; Vaidyanathan G; Zhao XG; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2010 Oct; 37(7):741-50. PubMed ID: 20870149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Characterization of the
    Striese F; Neuber C; Gräßel S; Arndt C; Ullrich M; Steinbach J; Pietzsch J; Bergmann R; Pietzsch HJ; Sihver W; Frenz M; Feldmann A; Bachmann MP
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.
    Kameswaran M; Pandey U; Dhakan C; Pathak K; Gota V; Vimalnath KV; Dash A; Samuel G
    Cancer Biother Radiopharm; 2015 Aug; 30(6):240-6. PubMed ID: 26066665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
    Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
    Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating
    Lakes AL; An DD; Gauny SS; Ansoborlo C; Liang BH; Rees JA; McKnight KD; Karsunky H; Abergel RJ
    Mol Pharm; 2020 Nov; 17(11):4270-4279. PubMed ID: 33044830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
    Milenic DE; Garmestani K; Chappell LL; Dadachova E; Yordanov A; Ma D; Schlom J; Brechbiel MW
    Nucl Med Biol; 2002 May; 29(4):431-42. PubMed ID: 12031878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [
    Zeng Z; Li L; Tao J; Liu J; Li H; Qian X; Yang Z; Zhu H
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1221-1232. PubMed ID: 38062170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.